Merck, known as MSD outside of the United States and Canada, announced the completion of the Prometheus Biosciences, Inc. (Prometheus) acquisition. Prometheus is now a wholly-owned subsidiary of Merck and the common stock of Prometheus will no longer be listed or traded on the Nasdaq Global Market.
